Comment on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naive type 2 diabetes patients:: cost-effectiveness analysis in the UK setting -: Reply

被引：0

作者：

Valentine, William J.

Palmer, Andrew J.

Lammert, Morten

Nicklasson, Lars

Foos, Volker

Roze, Stephane

机构：

[1] CORE, Ctr Outcomes Res, CH-4102 Binningen, Switzerland

[2] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark

[3] Novo Nordisk Inc, Princeton, NJ USA

来源：

CURRENT MEDICAL RESEARCH AND OPINION | 2006年 / 22卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：968 / 969

页数：2

共 50 条

[41] Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective
Evans, Marc
Gundgaard, Jens
Hansen, Brian Bekker
[J]. DIABETES THERAPY, 2016, 7 (04) : 809 - 823
[42] Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective
Marc Evans
Jens Gundgaard
Brian Bekker Hansen
[J]. Diabetes Therapy, 2016, 7 : 809 - 823
[43] COST EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO BIPHASIC INSULIN ASPART 30 FROM BIPHASIC HUMAN INSULIN 30 IN THE CZECH SETTING
Suchankova, E.
Dolezal, T.
Pisarikova, Z.
Rychna, K.
Bartaskova, D.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A405 - A406
[44] PROJECTED COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 IN TYPE 2 DIABETES PATIENTS SWITCHED FROM BIPHASIC HUMAN INSULIN IN THE UNITED STATES
Aagren, M.
Thomsen, T. L.
Knudsen, V. K.
[J]. VALUE IN HEALTH, 2009, 12 (03) : A10 - A10
[45] Evaluating the long-term cost-effectiveness of insulin aspart (novorapid®) versus human soluble insulin in patients with type 2 diabetes in Spain and Italy
Erny-Albrecht, W.
Goodall, G.
Townsend, C.
Kotchie, R.
Nielsen, S.
Valentine, W. J.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A260 - A260
[46] Biphasic insulin aspart 30 versus oral hypoglycemic agents in the treatment of type-2 diabetes: Long-term projection of clinical and cost outcomes in Sweden
Palmer, AJ
Lammert, M
Valentine, WJ
Ray, JA
Brandt, AS
Roze, S
[J]. VALUE IN HEALTH, 2005, 8 (06) : A160 - A160
[47] COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 50 VERSUS BIPHASIC HUMAN INSULIN 50 IN PEOPLE WITH TYPE 2 DIABETES MELLITUS IN CHINA
Wang, H.
Liu, X.
Wan, L.
Sun, X.
Chen, K.
Zhang, Y.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A897 - A898
[48] Long-term cost-effectiveness analysis of patients with type 2 diabetes mellitus inadequately controlled on thiazolidinedione therapy and either biphasic insulin aspart 30 or sulfonylurea
Nicklasson, L
Palmer, A
Cobden, D
Valentine, W
Roze, S
[J]. DIABETOLOGIA, 2005, 48 : A334 - A334
[49] Comparative evaluation of the long-term cost-effectiveness of biphasic insulin aspart 30 and insulin glargine in a sub-population of poorly controlled patients with Type-2 diabetes receiving oral antidiabetic agents
Cobden, D
Nicklasson, L
Raskin, P
Garber, A
Ray, JA
Valentine, W
Palmer, A
Roze, S
[J]. VALUE IN HEALTH, 2005, 8 (06) : A162 - A162
[50] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART (IDEGASP) COMPARED WITH BIPHASIC INSULIN ASPART (BIASP 30) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A MEXICAN HEALTHCARE PERSPECTIVE
Sanchez-Pedraza, V
Hansen, B. B.
Gundgaard, J.
Uranga Romano, Garca J.
Evans, M.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A672 - A672

← 1 2 3 4 5 →